Not long ago, Amyris and Gingko Bioworks were stock-market darlings, but the rout in tech stocks this year has been especially tough on these two. Shares of this synthetic biology start-up shot higher following its stock-market debut last year. The good times didn't last long, though, and now Gingko Bioworks stock is down more than 80% from its all-time high.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting